NanoViricides, Inc.
(OTC BB: NNVC.OB) (the "Company"), announced today that Dr. Eugene
Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent
FluCide animal study on November 19th at the Influenza Congress USA 2009
in Washington, DC (www.terrapinn.com/usaflu). These data clearly established
that the new version of FluCide is superior to the older version. The
data also showed extremely large survival lifetime improvement compared to an
extended therapy using oseltamivir (Tamiflu Roche).
Separately, Dr. Anil R. Diwan, President of the Company, presented a talk
on November 18th at the Nano and Clean Tech 2009 Conference (http://www.chemshow.com/includes/nano.pdf)
in New York City, held in conjunction and partnership with the Chem Show 2009
(http://www.chemshow.com).
Dr. Diwan gave a description of the nanomedicine technology on which the Company's
product platform is based. He then went on to discuss the successful development
of several drug candidates in a relatively short timeframe and with very small
R&D expenditures that NanoViricides Inc. has been able to achieve. "Our
achievements have clearly demonstrated that we can develop drug candidates against
new virus targets very quickly," he said. He explained that the multi-point
binding of a nanoviricide, enabled by the underlying TheraCour polymer,
results in a nanoscale "velcro" or zipper-like effect. This allows
the Company to employ virus-binding ligands with relatively low affinities successfully.
"Other drug development approaches require discovery of antibodies or
chemicals with very high affinities, sub-micromolar or better, which takes a
lot of time and money," he said, adding, "In contrast, our technology
allows us to use mimics of the natural and conserved binding sites of the viruses.
This allows rapid development. Also, it means that a virus is far less likely
to escape a nanoviricide compared to its escape rate against a highly specific
drug discovered using a conventional methodology."
The recent animal study of FluCide was conducted using the same total lethality
protocol employed in previous influenza studies by the Company. The new version
of FluCide drug candidate extended the lifespan of lethally infected mice to
334±11 hrs (or 14 days) on average. In contrast, mice treated with an
extended oseltamivir protocol survived for 193±3 hrs (or 8 days) on average.
Control infected mice survived for only 121±2 hrs (or 5 days). FluCide
was given as an IV injection, on alternate days, for five treatments. Oseltamivir
was given as oral, twice daily, each at 20mg/kg through life (or 14 treatments).
Previously, oseltamivir given using the customary protocol of oral, twice daily,
each at 20mg/kg for 4 days (8 treatments), has produced a survival time of 151±1
hrs (or 6.3 days) in this model. Several additional parameters have been evaluated
in this study. The Company expects to analyze the data from these additional
parameters as they are received in the near future.
The Company believes that the lifetime data demonstrate an unquestionable superiority
of the FluCide drug candidate compared to current drugs, and establish it as
a viable therapy against influenza. We believe that FluCide is likely the most
effective drug candidate in development against influenza, based on these results.
The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific,
MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated
directly into the lungs of mice. A repeat "booster" infection was
performed at 22 hrs. This is a highly lethal model, allowing the survival lifetimes
to be directly used for rank ordering of efficacy of drug candidates.
The Company has previously shown that a previous version of the FluCide drug
candidate was highly effective against two different clades of the H5N1 bird
flu virus, in addition to being highly effective against H1N1 in the mouse model.
The Company has recently improved the FluCide drug candidate, creating what
it believes to be a single drug candidate against all forms of influenza. The
Company believes that the data we presented at the Influenza Conference establish
this pan-influenza drug candidate as a leading anti-influenza drug in development.
Posted November 23rd, 2009
